Cd40lg (CD40 ligand) - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Cd40lg (CD40 ligand) Rattus norvegicus
Analyze
Symbol: Cd40lg
Name: CD40 ligand
RGD ID: 708418
Description: Enables CD40 receptor binding activity. Involved in several processes, including positive regulation of B cell proliferation; positive regulation of MHC class II biosynthetic process; and positive regulation of cytokine production. Located in several cellular components, including cell body; cell surface; and extracellular space. Used to study Ehrlich tumor carcinoma; artery disease (multiple); autoimmune disease (multiple); thrombosis; and vitamin B12 deficiency. Biomarker of atherosclerosis; coronary artery disease; perinatal necrotizing enterocolitis; periodontal disease; and pulmonary hypertension. Human ortholog(s) of this gene implicated in several diseases, including Kawasaki disease; autoimmune disease (multiple); combined T cell and B cell immunodeficiency (multiple); hematologic cancer (multiple); and lupus nephritis. Orthologous to human CD40LG (CD40 ligand); PARTICIPATES IN interleukin-4 signaling pathway; obesity pathway; allograft rejection pathway; INTERACTS WITH 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 2,3,7,8-tetrachlorodibenzodioxine; 4-aminopyridine.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: CD40 ligand CD154; CD40-L; Cd40l; LOC84349; Tnfsf5; tumor necrosis factor (ligand) superfamily, member 5; tumor necrosis factor ligand superfamily member 5
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.2X135,127,119 - 135,138,302 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 EnsemblX135,126,969 - 135,138,306 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_UtxX137,323,952 - 137,335,135 (+)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.0X140,881,620 - 140,892,805 (+)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.0X138,451,019 - 138,462,204 (+)NCBIRnor_WKY
Rnor_6.0X159,703,703 - 159,714,886 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 EnsemblX159,703,578 - 159,716,562 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0X154,330,893 - 154,341,954 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4X141,925,019 - 141,937,183 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1X141,998,451 - 142,010,616 (+)NCBI
CeleraX143,160,596 - 143,171,765 (+)NCBICelera
Cytogenetic MapXq37NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acquired immunodeficiency syndrome  (ISO)
Acute Coronary Syndrome  (ISO)
acute lymphoblastic leukemia  (ISO)
allergic disease  (ISO)
allergic rhinitis  (ISO)
Alzheimer's disease  (ISO)
amyotrophic lateral sclerosis  (ISO)
anti-basement membrane glomerulonephritis  (IMP)
antiphospholipid syndrome  (ISO)
aplastic anemia  (ISO)
asthma  (ISO)
atherosclerosis  (IDA,IEP,ISO)
autistic disorder  (ISO)
autoimmune disease  (ISO)
autoimmune thrombocytopenic purpura  (ISO)
B-Cell Chronic Lymphocytic Leukemia  (ISO)
Behcet's disease  (ISO)
Brain Injuries  (IDA,IEP)
calcification of aortic valve  (IDA)
cardiovascular system disease  (ISO)
carotid artery disease  (ISO)
CD40 ligand deficiency  (ISO)
Cholangiofibrosis  (IDA)
Chromosome Breakage  (ISO)
Chromosome Xq26.3 Duplication Syndrome  (ISO)
Chronic Allograft Dysfunction  (IDA)
chronic lymphocytic leukemia  (ISO)
Colonic Neoplasms  (ISO)
combined T cell and B cell immunodeficiency  (ISO)
common variable immunodeficiency  (ISO)
Congenital Heart Defects, Multiple Types, 1, X-Linked  (ISO)
congestive heart failure  (ISO)
coronary artery disease  (IEP,ISO)
Coronary Disease  (IDA)
crescentic glomerulonephritis  (ISO)
cutaneous lupus erythematosus  (ISO)
cystic fibrosis  (ISO)
dermatomyositis  (ISO)
diabetes mellitus  (ISO)
diabetic angiopathy  (ISO)
Diabetic Nephropathies  (ISO)
Discoid Lupus Erythematosus  (ISO)
dysgammaglobulinemia  (ISO)
Ehrlich tumor carcinoma  (IDA)
end stage renal disease  (ISO)
eosinophilic esophagitis  (ISO)
erythema multiforme  (ISO)
essential thrombocythemia  (ISO)
Experimental Arthritis  (IDA,IEP,ISO)
Experimental Autoimmune Myasthenia Gravis  (IMP)
Experimental Autoimmune Neuritis  (IEP)
Experimental Autoimmune Uveoretinitis  (ISO)
Experimental Diabetes Mellitus  (IEP,ISO)
Experimental Liver Neoplasms  (ISO)
factor VIII deficiency  (ISO)
familial hyperlipidemia  (ISO)
Fibrosis  (ISO)
follicular lymphoma  (ISO)
genetic disease  (ISO)
Graft vs Host Disease  (ISO)
granulomatosis with polyangiitis  (ISO)
Graves' disease  (ISO)
Hashimoto Disease  (ISO)
HELLP syndrome  (ISO)
hepatocellular carcinoma  (ISO)
herpes simplex  (ISO)
Hodgkin's lymphoma  (ISO)
human immunodeficiency virus infectious disease  (ISO)
hyper IgM syndrome  (ISO)
Hypercholesterolemia  (IDA,IEP,ISO)
inflammatory bowel disease  (ISS)
Kawasaki disease  (ISO)
kidney disease  (ISO)
lichen planus  (ISO)
lupus nephritis  (ISO)
Lyme Neuroborreliosis  (ISO)
malaria  (ISO)
membranous glomerulonephritis  (ISO)
Metabolic Syndrome  (ISO)
Middle East respiratory syndrome  (ISO)
migraine  (ISO)
multiple myeloma  (ISO)
Murine Acquired Immunodeficiency Syndrome  (ISO)
myocardial infarction  (ISO)
Myocardial Ischemia  (IDA,IEP)
narcolepsy  (ISO)
Necrosis  (ISO)
nephrosis  (ISO)
obesity  (ISO)
ovarian disease  (ISO)
Ovarian Neoplasms  (ISO)
Overactive Urinary Bladder  (ISO)
pemphigus  (ISO)
Penetrating Wounds  (IDA)
perinatal necrotizing enterocolitis  (IEP)
periodontal disease  (IEP)
periodontitis  (ISO)
peritonitis  (ISO)
pneumonia  (ISO)
pre-eclampsia  (IMP,ISO)
Primary Graft Dysfunction  (ISO)
pulmonary hypertension  (IEP,ISO)
Reperfusion Injury  (IMP,ISO)
Sepsis  (IEP)
Shock  (ISO)
sickle cell anemia  (ISO)
Sjogren's syndrome  (ISO)
Subacute Combined Degeneration  (IDA,IEP)
syndromic X-linked intellectual disability Lubs type  (ISO)
systemic lupus erythematosus  (ISO)
thrombocytopenia  (ISO)
thrombosis  (IDA,ISO)
tick-borne encephalitis  (ISO)
transient cerebral ischemia  (ISO)
Transplant Rejection  (IMP,ISO)
type 1 diabetes mellitus  (IMP,ISO)
type 2 diabetes mellitus  (ISO)
urinary bladder cancer  (ISO)
Vascular Calcification  (ISO)
Viral Myocarditis  (IMP,ISO)
visceral leishmaniasis  (ISO)
vitamin B12 deficiency  (IDA)
X-linked hyper IgM syndrome  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(R)-mevalonic acid  (ISO)
1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane  (EXP)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
3,3'-diindolylmethane  (ISO)
4-aminopyridine  (EXP)
5-fluorouracil  (ISO)
acetylsalicylic acid  (ISO)
ADP  (ISO)
all-trans-retinoic acid  (ISO)
ammonium chloride  (EXP)
amphetamine  (EXP)
antirheumatic drug  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenous acid  (ISO)
asperentin  (ISO)
atorvastatin calcium  (ISO)
barium sulfate  (EXP)
benzo[a]pyrene  (EXP,ISO)
bezafibrate  (ISO)
bis(2-chloroethyl) sulfide  (ISO)
bisphenol A  (EXP)
calcitriol  (ISO)
candesartan  (ISO)
carbon atom  (ISO)
ceric oxide  (EXP)
chlorpyrifos  (ISO)
cholesterol  (EXP)
cisplatin  (ISO)
clopidogrel  (ISO)
curcumin  (ISO)
DDE  (EXP)
diarsenic trioxide  (ISO)
dibenziodolium  (ISO)
dioxygen  (ISO)
dipyridamole  (ISO)
doxorubicin  (ISO)
elemental carbon  (ISO)
eptifibatide  (ISO)
ethanol  (EXP)
etoposide  (ISO)
fenofibrate  (ISO)
fingolimod hydrochloride  (ISO)
furan  (EXP)
Fusarenone X  (ISO)
gemcitabine  (ISO)
glutathione  (ISO)
glyphosate  (ISO)
heparin  (ISO)
hydrogen peroxide  (ISO)
hydroxychloroquine  (ISO)
hydroxysafflor yellow A  (EXP)
ionomycin  (ISO)
isoflurane  (EXP)
lipopolysaccharide  (ISO)
medroxyprogesterone acetate  (ISO)
metformin  (ISO)
mycophenolic acid  (ISO)
mycotoxin  (ISO)
N-acetyl-L-cysteine  (EXP,ISO)
neoechinulin A  (ISO)
nickel dichloride  (ISO)
ozone  (ISO)
p-menthan-3-ol  (ISO)
paclitaxel  (ISO)
pentobarbital  (EXP)
phorbol 13-acetate 12-myristate  (ISO)
quercetin  (ISO)
reactive oxygen species  (ISO)
resveratrol  (EXP)
rotenone  (EXP,ISO)
silicon dioxide  (ISO)
simvastatin  (ISO)
sodium arsenite  (ISO)
sodium fluoride  (ISO)
sterigmatocystin  (ISO)
titanium dioxide  (ISO)
vemurafenib  (ISO)
vincaleukoblastine  (ISO)
vinclozolin  (EXP)
vinorelbine  (ISO)
zoledronic acid  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function

References

References - curated
# Reference Title Reference Citation
1. Tolerance induction by costimulator blockade in 100 cGy treated hosts with varying degrees of genetic disparity. Abedi M, etal., Leukemia. 2003 Sep;17(9):1871-9.
2. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Ahn ER, etal., Thromb Res. 2004;114(2):143-8.
3. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Aruffo A, etal., Cell. 1993 Jan 29;72(2):291-300.
4. The expression and concentration of CD40 ligand in normal pregnancy, preeclampsia, and hemolytic anemia, elevated liver enzymes and low platelet count (HELLP) syndrome. Azzam HA, etal., Blood Coagul Fibrinolysis. 2013 Jan;24(1):71-5. doi: 10.1097/MBC.0b013e32835a8aca.
5. Disruption of CD40/CD40-ligand interactions in a retinal autoimmunity model results in protection without tolerance. Bagenstose LM, etal., J Immunol. 2005 Jul 1;175(1):124-30.
6. Costimulation and autoimmune diabetes in BB rats. Beaudette-Zlatanova BC, etal., Am J Transplant. 2006 May;6(5 Pt 1):894-902.
7. Inhibition of the CD40-CD40ligand pathway prevents murine membranous glomerulonephritis. Biancone L, etal., Kidney Int. 1995 Aug;48(2):458-68.
8. Soluble CD40 ligand, high sensitive C-reactive protein and fetuin-A levels in patients with essential thrombocythemia. Bilgir F, etal., Transfus Apher Sci. 2012 Feb;46(1):67-71. doi: 10.1016/j.transci.2011.11.013. Epub 2011 Dec 23.
9. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. Blanchard C, etal., J Allergy Clin Immunol. 2011 Jan;127(1):208-17, 217.e1-7.
10. Blocking the CD40-CD40L interaction by CD40-Ig reduces disease progress in murine myocarditis induced by CVB3. Bo H, etal., Cardiovasc Pathol. 2010 Nov-Dec;19(6):371-6. doi: 10.1016/j.carpath.2009.10.002. Epub 2009 Nov 14.
11. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Boumpas DT, etal., Arthritis Rheum. 2003 Mar;48(3):719-27.
12. Urocortin-1 Mediated Cardioprotection Involves XIAP and CD40-Ligand Recovery: Role of EPAC2 and ERK1/2. Calderon-Sanchez E, etal., PLoS One. 2016 Feb 3;11(2):e0147375. doi: 10.1371/journal.pone.0147375. eCollection 2016.
13. Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Calingasan NY, etal., Neurobiol Aging. 2002 Jan-Feb;23(1):31-9.
14. CD40-CD154 expression in calcified and non-calcified coronary lesions of patients with chronic renal failure. Campean V, etal., Atherosclerosis. 2007 Jan;190(1):156-66. Epub 2006 Feb 21.
15. The CD40/CD40 ligand system is involved in the pathogenesis of pemphigus. Caproni M, etal., Clin Immunol. 2007 Jul;124(1):22-5. Epub 2007 May 24.
16. The CD40/CD40 ligand system in the skin of patients with subacute cutaneous lupus erythematosus. Caproni M, etal., J Rheumatol. 2007 Dec;34(12):2412-6. Epub 2007 Nov 15.
17. Exploring the role of short-course cyclosporin a therapy in preventing homograft valve calcification after transplantation. Chang Q, etal., Cell Immunol. 2014 Jan;287(1):36-45. doi: 10.1016/j.cellimm.2013.11.008. Epub 2013 Dec 8.
18. The ginsenoside metabolite compound K exerts its anti-inflammatory activity by downregulating memory B cell in adjuvant-induced arthritis. Chen J, etal., Pharm Biol. 2016 Jul;54(7):1280-8. doi: 10.3109/13880209.2015.1074254. Epub 2016 May 24.
19. Evaluating antithrombotic activity of HY023016 on rat hypercoagulable model. Chen QF, etal., Eur J Pharmacol. 2016 Jun 15;781:190-7. doi: 10.1016/j.ejphar.2016.04.023. Epub 2016 Apr 13.
20. Soluble CD40L (CD154) is increased in patients with shock. Chew M, etal., Inflamm Res. 2010 Nov;59(11):979-82. Epub 2010 May 20.
21. Increased concentrations of soluble CD40 ligand may help to identify type 1 diabetic adolescents and young adults at risk for developing persistent microalbuminuria. Chiarelli F, etal., Diabetes Metab Res Rev. 2008 Oct;24(7):570-6.
22. Norepinephrine induces systolic failure and inhibits antiapoptotic genes in a polymicrobial septic rat model. Chopra M, etal., Life Sci. 2010 Dec 18;87(23-26):672-8. doi: 10.1016/j.lfs.2010.09.029. Epub 2010 Oct 7.
23. Low CD40L levels and relative lymphopenia in narcoleptic patients. Coelho FM, etal., Hum Immunol. 2011 Oct;72(10):817-20. doi: 10.1016/j.humimm.2011.05.024. Epub 2011 May 30.
24. Blockade of CD40 ligand for intercellular communication reduces hypertension, placental oxidative stress, and AT1-AA in response to adoptive transfer of CD4+ T lymphocytes from RUPP rats. Cornelius DC, etal., Am J Physiol Regul Integr Comp Physiol. 2015 Nov 15;309(10):R1243-50. doi: 10.1152/ajpregu.00273.2015. Epub 2015 Aug 26.
25. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Curran KJ, etal., Mol Ther. 2015 Apr;23(4):769-78. doi: 10.1038/mt.2015.4. Epub 2015 Jan 13.
26. Cilostazol exerts antiplatelet and anti-inflammatory effects through AMPK activation and NF-kB inhibition on hypercholesterolemic rats. da Motta NA and de Brito FC, Fundam Clin Pharmacol. 2016 Aug;30(4):327-37. doi: 10.1111/fcp.12195. Epub 2016 Mar 31.
27. Soluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-up. Desideri G, etal., Nephrol Dial Transplant. 2011 Sep;26(9):2983-8. doi: 10.1093/ndt/gfq823. Epub 2011 Feb 8.
28. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Devaraj S, etal., Diabetes. 2006 Mar;55(3):774-9.
29. CD40 ligand induces an antileukemia immune response in vivo. Dilloo D, etal., Blood. 1997 Sep 1;90(5):1927-33.
30. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Durie FH, etal., Science. 1993 Sep 3;261(5126):1328-30.
31. Role of CD28/CD80-86 and CD40/CD154 costimulatory interactions in host defense to primary herpes simplex virus infection. Edelmann KH and Wilson CB, J Virol. 2001 Jan;75(2):612-21.
32. Anti-C1q antibodies, sCD40L, TWEAK and CD4/CD8 ratio in systemic lupus erythematosus and their relations to disease activity and renal involvement. ElGendi SS and El-Sherif WT, Egypt J Immunol. 2009;16(1):135-48.
33. Molecular genetic analysis of Hungarian patients with the hyper-immunoglobulin M syndrome. Erdos M, etal., Mol Immunol. 2008 Jan;45(1):278-82. Epub 2007 Jun 5.
34. Molecular and functional analysis of a novel recombinant clone of rat (Rattus norvegicus) CD40 ligand (CD40L) gene. Esendagli G, etal., Mol Biol Rep. 2009 Jan;36(1):83-9. Epub 2007 Oct 7.
35. Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis. Estep JM, etal., Obes Surg. 2009 May;19(5):617-24. Epub 2009 Mar 12.
36. Increased soluble CD40 ligand levels in cystic fibrosis. Falco A, etal., J Thromb Haemost. 2004 Apr;2(4):557-60.
37. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Fateh-Moghadam S, etal., Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1299-303. Epub 2005 Apr 7.
38. Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura. Feng X, etal., J Thromb Haemost. 2012 Aug;10(8):1616-23. doi: 10.1111/j.1538-7836.2012.04757.x.
39. Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behcet disease patients. Fernandez Bello I, etal., Thromb Haemost. 2012 Jan;107(1):88-98. doi: 10.1160/TH11-08-0556. Epub 2011 Nov 24.
40. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
41. Effect of resveratrol on platelet activation in hypercholesterolemic rats: CD40-CD40L system as a potential target. Gocmen AY, etal., Appl Physiol Nutr Metab. 2011 Jun;36(3):323-30. doi: 10.1139/h11-022. Epub 2011 May 16.
42. Effect of atorvastatin on atherosclerotic plaque formation and platelet activation in hypercholesterolemic rats. Gocmen AY, etal., Can J Physiol Pharmacol. 2013 Sep;91(9):680-5. doi: 10.1139/cjpp-2012-0325. Epub 2013 Apr 8.
43. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome--the Chennai Urban Rural Epidemiology Study. Gokulakrishnan K, etal., Metabolism. 2006 Feb;55(2):237-42.
44. Antibody to the ligand for CD40 (gp39) inhibits murine AIDS-associated splenomegaly, hypergammaglobulinemia, and immunodeficiency in disease-susceptible C57BL/6 mice. Green KA, etal., J Virol. 1996 Apr;70(4):2569-75.
45. Evidence for a continued requirement for CD40/CD40 ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine AIDS. Green KA, etal., Virology. 1998 Feb 15;241(2):260-8.
46. Platelet CD40 ligand and bleeding during P2Y12 inhibitor treatment in acute coronary syndrome. Grosdidier C, etal., Res Pract Thromb Haemost. 2019 Jul 26;3(4):684-694. doi: 10.1002/rth2.12244. eCollection 2019 Oct.
47. Soluble CD40 ligand and prolactin levels in migraine patients during interictal period. Guldiken S, etal., J Headache Pain. 2011 Jun;12(3):355-60. Epub 2011 Feb 18.
48. Local activation of dendritic cells leads to insulitis and development of insulin-dependent diabetes in transgenic mice expressing CD154 on the pancreatic beta-cells. Haase C, etal., Diabetes. 2004 Oct;53(10):2588-95.
49. Platelet activation in patients with atherosclerotic renal artery stenosis undergoing stent revascularization. Haller S, etal., Clin J Am Soc Nephrol. 2011 Sep;6(9):2185-91. doi: 10.2215/CJN.03140411. Epub 2011 Aug 4.
50. Nucleotide sequence of the rat CD40 ligand. Hallett KM and Oaks MK, DNA Seq 2000;10(6):405-6.
51. Immunogene therapy by adenovirus vector expressing CD40 ligand for metastatic liver cancer in rats. Hanyu K, etal., Anticancer Res. 2008 Sep-Oct;28(5A):2785-9.
52. A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model. Hashem AM, etal., J Infect Dis. 2019 Oct 8;220(10):1558-1567. doi: 10.1093/infdis/jiz137.
53. Cutting Edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. Higuchi T, etal., J Immunol. 2002 Jan 1;168(1):9-12.
54. Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis. Hocher B, etal., J Am Soc Nephrol. 2007 Apr;18(4):1323-30. Epub 2007 Feb 21.
55. Adenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma. Iida T, etal., Cancer Sci. 2008 Oct;99(10):2097-103.
56. Immunogene therapy against colon cancer metastasis using an adenovirus vector expressing CD40 ligand. Iida T, etal., Surgery. 2010 Nov;148(5):925-35. Epub 2010 Apr 7.
57. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. Im SH, etal., J Immunol. 2001 Jun 1;166(11):6893-8.
58. Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment. Imbeault M, etal., J Virol. 2011 Mar;85(5):2189-200. Epub 2010 Dec 22.
59. CD40/CD40 ligand signaling in mouse cerebral microvasculature after focal ischemia/reperfusion. Ishikawa M, etal., Circulation. 2005 Apr 5;111(13):1690-6. Epub 2005 Mar 28.
60. Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand. Jain A, etal., Blood. 2011 Aug 12.
61. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Jakubowski JA, etal., Thromb Res. 2014 Feb;133(2):190-5. doi: 10.1016/j.thromres.2013.12.008. Epub 2013 Dec 7.
62. Surface camouflage of pancreatic islets using 6-arm-PEG-catechol in combined therapy with tacrolimus and anti-CD154 monoclonal antibody for xenotransplantation. Jeong JH, etal., Biomaterials. 2011 Nov;32(31):7961-70. doi: 10.1016/j.biomaterials.2011.06.068. Epub 2011 Aug 9.
63. [Changes of soluble CD40 ligand in patients with hyperlipidemia of blood stasis syndrome and its clinical significance]. Jin L, etal., Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Mar;31(3):315-8.
64. Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. Kairaitis L, etal., Kidney Int. 2003 Oct;64(4):1265-72.
65. Serum soluble CD40L concentration depending on the stage of multiple myeloma and its correlation with selected angiogenic cytokines. Kaminska J, etal., Pol Arch Med Wewn. 2016 May 31;126(5):321-9. doi: 10.20452/pamw.3427. Epub 2016 May 31.
66. Association of soluble CD40 ligand with carotid atherosclerosis in Japanese type 1 diabetic patients. Katakami N, etal., Diabetologia. 2006 Jul;49(7):1670-6. Epub 2006 May 12.
67. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Komura K, etal., Ann Rheum Dis. 2008 Jun;67(6):867-72. Epub 2007 Sep 6.
68. CD40/154 blockade and rejection of islet allografts in the streptozotocin and autoimmune diabetic rat. Kover KL, etal., Pediatr Diabetes. 2001 Dec;2(4):178-83.
69. CD40 Gene polymorphisms associated with susceptibility and coronary artery lesions of Kawasaki disease in the Taiwanese population. Kuo HC, etal., ScientificWorldJournal. 2012;2012:520865. doi: 10.1100/2012/520865. Epub 2012 May 2.
70. Repetitive hyperbaric oxygenation attenuates reactive astrogliosis and suppresses expression of inflammatory mediators in the rat model of brain injury. Lavrnja I, etal., Mediators Inflamm. 2015;2015:498405. doi: 10.1155/2015/498405. Epub 2015 Apr 20.
71. The CD40-CD154 co-stimulation pathway mediates innate immune injury in adriamycin nephrosis. Lee VW, etal., Nephrol Dial Transplant. 2010 Mar;25(3):717-30. doi: 10.1093/ndt/gfp569. Epub 2009 Nov 4.
72. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. Lee WI, etal., Blood. 2005 Mar 1;105(5):1881-90. Epub 2004 Sep 9.
73. Disruption of antigen-induced inflammatory responses in CD40 ligand knockout mice. Lei XF, etal., J Clin Invest. 1998 Mar 15;101(6):1342-53.
74. [Effects of electroacupuncture intervention on blood lipid levels and expression of CD 40 L and MMP-9 in the coronary artery tissue in coronary heart disease rats]. Li M, etal., Zhen Ci Yan Jiu. 2013 Apr;38(2):123-8.
75. Effect of curcumin on permeability of coronary artery and expression of related proteins in rat coronary atherosclerosis heart disease model. Li X, etal., Int J Clin Exp Pathol. 2015 Jun 1;8(6):7247-53. eCollection 2015.
76. Adaptive immune response in osteoclastic bone resorption induced by orally administered Aggregatibacter actinomycetemcomitans in a rat model of periodontal disease. Li Y, etal., Mol Oral Microbiol. 2010 Aug;25(4):275-92.
77. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Lievens D, etal., Blood. 2010 Nov 18;116(20):4317-27. Epub 2010 Aug 12.
78. Elevated circulating levels of soluble CD-40 ligand in haemodialysis patients with symptomatic coronary heart disease. Lim PS, etal., Nephrology (Carlton). 2008 Dec;13(8):677-83. doi: 10.1111/j.1440-1797.2008.00999.x. Epub 2008 Nov 17.
79. X-linked hyper-immunoglobulin M syndrome: molecular genetic study and long-time follow-up of three generations of a Chinese family. Lin SC, etal., Int Arch Allergy Immunol. 2006;140(1):1-8. Epub 2006 Feb 23.
80. From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Lincecum JM, etal., Nat Genet. 2010 May;42(5):392-9. Epub 2010 Mar 28.
81. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Liu Y, etal., Cancer Gene Ther. 2005 Feb;12(2):122-32.
82. [Protective effect of Buyanghuanwu Decoction on myocardial ischemia induced by isoproterenol in rats]. Liu Y, etal., Zhong Yao Cai. 2009 Mar;32(3):380-3.
83. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Loskog AS, etal., Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8816-21.
84. Role of CD40-CD154 pathway in the rejection of concordant and discordant xenogeneic islets. Mai G, etal., Transplant Proc. 2005 Jan-Feb;37(1):460-2.
85. Immune modulation and apoptosis induction: Two sides of antitumoural activity of a standardised herbal formulation of Withania somnifera. Malik F, etal., Eur J Cancer. 2009 May;45(8):1494-509. doi: 10.1016/j.ejca.2009.01.034. Epub 2009 Mar 5.
86. Blockade of T cell costimulatory signals using adenovirus vectors prevents both the induction and the progression of experimental autoimmune myocarditis. Matsui Y, etal., J Mol Cell Cardiol. 2002 Mar;34(3):279-95. doi: 10.1006/jmcc.2001.1511.
87. CD40 ligand (CD154) takes part in regulation of the transition to mononuclear cell dominance during peritonitis. Mazar J, etal., Kidney Int. 2005 Apr;67(4):1340-9.
88. Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes. Meabed MH, etal., Hematology. 2007 Aug;12(4):301-7.
89. Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. Mehling A, etal., J Exp Med. 2001 Sep 3;194(5):615-28.
90. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
91. Involvement of CD40-CD40L signaling in postischemic lung injury. Moore TM, etal., Am J Physiol Lung Cell Mol Physiol. 2002 Dec;283(6):L1255-62. Epub 2002 Aug 9.
92. Prevention of autoimmune diabetes in the DRBB rat by CD40/154 blockade. Moore WV, etal., J Autoimmun. 2002 Nov;19(3):139-45.
93. Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Murray HW, etal., Infect Immun. 2003 Nov;71(11):6453-62.
94. Serum CD40/CD40L system in Graves' disease and Hashimoto's thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response. Mysliwiec J, etal., Immunol Invest. 2007;36(3):247-57.
95. Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary glands of patients with Sjogren's syndrome. Nakamura H, etal., Lab Invest. 1999 Mar;79(3):261-9.
96. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism. Nakamura M, etal., Rheumatology (Oxford). 2006 Feb;45(2):150-6. Epub 2005 Sep 27.
97. CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. Nesbeth YC, etal., J Immunol. 2010 May 15;184(10):5654-62. Epub 2010 Apr 16.
98. CD40, CD154, Bax and Bcl-2 expression in Sjogren's syndrome salivary glands: a putative anti-apoptotic role during its effector phases. Ohlsson M, etal., Scand J Immunol. 2002 Dec;56(6):561-71.
99. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
100. T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. Pantenburg B, etal., J Immunol. 2002 Oct 1;169(7):3686-93.
101. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Patel VL, etal., Br J Haematol. 2008 May;141(4):545-8. doi: 10.1111/j.1365-2141.2008.07039.x. Epub 2008 Mar 12.
102. Abrogation of pathogenic IgG autoantibody production in CD40L gene-deleted lupus-prone New Zealand Black mice. Pau E, etal., Clin Immunol. 2011 May;139(2):215-27. Epub 2011 Mar 17.
103. alpha beta T cell regulation and CD40 ligand dependence in murine systemic autoimmunity. Peng SL, etal., J Immunol. 1997 Mar 1;158(5):2464-70.
104. Role of CD40-CVD40L in mouse severe malaria. Piguet PF, etal., Am J Pathol. 2001 Aug;159(2):733-42.
105. Thrombocytopenia in an animal model of malaria is associated with an increased caspase-mediated death of thrombocytes. Piguet PF, etal., Apoptosis. 2002 Apr;7(2):91-8.
106. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
107. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
108. CD40L Deficiency Ameliorates Adipose Tissue Inflammation and Metabolic Manifestations of Obesity in Mice. Poggi M, etal., Arterioscler Thromb Vasc Biol. 2011 Oct;31(10):2251-60. Epub 2011 Aug 4.
109. Gene expression profiling of Lucilia sericata larvae extraction/secretion-treated skin wounds. Polat E, etal., Gene. 2014 Oct 25;550(2):223-9. doi: 10.1016/j.gene.2014.08.033. Epub 2014 Aug 19.
110. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Quezada SA, etal., Arthritis Rheum. 2003 Sep;48(9):2541-54.
111. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Reipert BM, etal., Thromb Haemost. 2001 Dec;86(6):1345-52.
112. Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves' thyroid tissues xenografted into severe combined immunodeficient (SCID) mice. Resetkova E, etal., Thyroid. 1996 Aug;6(4):267-73.
113. Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis. Reynolds J, etal., Kidney Int. 2004 Oct;66(4):1444-52.
114. GOA pipeline RGD automated data pipeline
115. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
116. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
117. Comprehensive gene review and curation RGD comprehensive gene curation
118. Human X-linked variable immunodeficiency caused by a hypomorphic mutation in XIAP in association with a rare polymorphism in CD40LG. Rigaud S, etal., Blood. 2011 Jul 14;118(2):252-61. Epub 2011 May 4.
119. Effects of xinfeng capsules on expression of platelet granule membrane protein 140 and platelet cluster of differentiation 40 ligand in peripheral blood of adjuvant arthritis rats. Rui-Kai Z and Jian L, Int J Rheumatol. 2012;2012:139696. doi: 10.1155/2012/139696. Epub 2012 May 7.
120. Intrinsic renal cell expression of CD40 directs Th1 effectors inducing experimental crescentic glomerulonephritis. Ruth AJ, etal., J Am Soc Nephrol. 2003 Nov;14(11):2813-22.
121. Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients. Santini E, etal., J Endocrinol Invest. 2008 Jul;31(7):660-5.
122. Hypothermic oxygenated perfusion (HOPE) protects from biliary injury in a rodent model of DCD liver transplantation. Schlegel A, etal., J Hepatol. 2013 Nov;59(5):984-91. doi: 10.1016/j.jhep.2013.06.022. Epub 2013 Jun 29.
123. Expression of costimulatory molecule CD40 in murine heart with acute myocarditis and reduction of inflammation by treatment with anti-CD40L/B7-1 monoclonal antibodies. Seko Y, etal., Circ Res. 1998 Aug 24;83(4):463-9.
124. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Sfikakis PP, etal., Arthritis Rheum. 2005 Feb;52(2):501-13.
125. CD40 ligand in pathogenesis of autoimmune ovarian disease of day 3-thymectomized mice: implication for CD40 ligand antibody therapy. Sharp C, etal., J Immunol. 2003 Feb 15;170(4):1667-74.
126. Alloimmune activation enhances innate tissue inflammation/injury in a mouse model of liver ischemia/reperfusion injury. Shen X, etal., Am J Transplant. 2010 Aug;10(8):1729-37.
127. Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection. Shoker A, etal., Transplantation. 2000 Aug 15;70(3):497-505.
128. The Role of Type I Interferon Subtypes and Interferon-Gamma in Type I Interferon Diabetes Inhibitory Activity in the NOD Mouse. Sobel D, etal., J Interferon Cytokine Res. 2016 Apr;36(4):238-46. doi: 10.1089/jir.2014.0232. Epub 2015 Dec 30.
129. Generation and characterization of a novel anti-rat CD40L antibody with inhibitory activities in vitro and in vivo. Stax AM, etal., J Immunol Methods. 2008 Jun 1;335(1-2):46-52. Epub 2008 Mar 20.
130. CD40L stimulation of rat dendritic cells specifically favors the IL-12/IL-10 ratio resulting in a strong T cell stimulatory capacity. Stax AM, etal., Mol Immunol. 2008 May;45(9):2641-50. Epub 2008 Feb 8.
131. beta1-Adrenoceptor antibody-induced increase in soluble CD40 ligand release in chronic periodontitis patients: role of prostaglandin E(2). Sterin-Borda L, etal., Exp Physiol. 2012 Sep;97(9):1030-9. doi: 10.1113/expphysiol.2012.065748. Epub 2012 Apr 20.
132. Allogenic mixed chimerism induced by nonlymphoablative regimen including donor BMT with low-dose TBI and anti-CD40L cured proliferative glomerulonephritis in lupus mice. Takeuchi E and Takeuchi Y, Ann N Y Acad Sci. 2007 Sep;1110:362-7.
133. Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. Tomasson G, etal., J Rheumatol. 2011 Jun;38(6):1048-54. Epub 2011 Mar 16.
134. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Tousoulis D, etal., Eur J Clin Invest. 2007 Aug;37(8):623-8.
135. Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma. Tsirakis G, etal., Med Oncol. 2012 Dec;29(4):2396-401. doi: 10.1007/s12032-012-0203-2. Epub 2012 Mar 9.
136. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Tyagi P, etal., Int Urol Nephrol. 2010 Sep;42(3):629-35. doi: 10.1007/s11255-009-9647-5. Epub 2009 Sep 26.
137. Soluble CD40 ligand in acute and chronic heart failure. Ueland T, etal., Eur Heart J. 2005 Jun;26(11):1101-7. Epub 2005 Feb 16.
138. The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people. Unek IT, etal., Clin Med Res. 2010 Jul;8(2):89-95.
139. Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome. Unek IT, etal., Metabolism. 2010 Mar;59(3):305-13. Epub 2009 Dec 16.
140. A common SNP in the CD40 region is associated with systemic lupus erythematosus and correlates with altered CD40 expression: implications for the pathogenesis. Vazgiourakis VM, etal., Ann Rheum Dis. 2011 Sep 12.
141. Increased levels of the CD40:CD40 ligand dyad in the cerebrospinal fluid of rats with vitamin B12(cobalamin)-deficient central neuropathy. Veber D, etal., J Neuroimmunol. 2006 Jul;176(1-2):24-33. Epub 2006 May 22.
142. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Wang CL, etal., Pediatrics. 2003 Feb;111(2):E140-7.
143. Protective effects of tanshinone A on endothelial progenitor cells injured by tumor necrosis factor-alpha. Wang XX, etal., Mol Med Rep. 2015 Sep;12(3):4055-62. doi: 10.3892/mmr.2015.3969. Epub 2015 Jun 22.
144. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Wierda WG, etal., Leukemia. 2010 Nov;24(11):1893-900. doi: 10.1038/leu.2010.191. Epub 2010 Sep 30.
145. Modified serum profiles of inflammatory and vasoconstrictive factors in patients with emotional stress-induced acute coronary syndrome during World Cup Soccer 2006. Wilbert-Lampen U, etal., J Am Coll Cardiol. 2010 Feb 16;55(7):637-42.
146. The expression of CD40-CD40L and activities of matrix metalloproteinases in atherosclerotic rats. Wu M and Li YG, Mol Cell Biochem. 2006 Jan;282(1-2):141-6.
147. Ileal immune dysregulation in necrotizing enterocolitis: role of CD40/CD40L in the pathogenesis of disease. Xu J, etal., J Pediatr Gastroenterol Nutr. 2011 Feb;52(2):140-6.
148. Combination of IL-1 receptor antagonist, IL-20 and CD40 ligand for the prediction of acute cellular renal allograft rejection. Xu X, etal., J Clin Immunol. 2013 Jan;33(1):280-7. doi: 10.1007/s10875-012-9777-x. Epub 2012 Sep 5.
149. Blockade by nifedipine of advanced glycation end product-induced CD40-CD40 ligand interaction in endothelial cells. Yamagishi S, etal., Drugs Exp Clin Res. 2005;31(5-6):221-6.
150. Pigment epithelium-derived factor (PEDF) inhibits diabetes- or advanced glycation end product (AGE)-induced platelet CD40 ligand overexpression in rats. Yamagishi SI, etal., Int J Cardiol. 2009 Feb 21.
151. Protective effects of chinese traditional medicine buyang huanwu decoction on myocardial injury. Yang G, etal., Evid Based Complement Alternat Med. 2011;2011:930324. doi: 10.1093/ecam/nep013. Epub 2011 Jun 5.
152. Zinc finger protein A20 protects rats against chronic liver allograft dysfunction. Yang J, etal., World J Gastroenterol. 2012 Jul 21;18(27):3537-50. doi: 10.3748/wjg.v18.i27.3537.
153. Interruption of CD40 Pathway Improves Efficacy of Transplanted Endothelial Progenitor Cells in Monocrotaline Induced Pulmonary Arterial Hypertension. YanYun P, etal., Cell Physiol Biochem. 2015;36(2):683-96.
154. Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Yngen M, etal., Diabetologia. 2004 Mar;47(3):537-40. Epub 2004 Feb 13.
155. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Younes A, etal., Br J Haematol. 1998 Jan;100(1):135-41.
156. Soluble CD40 and soluble CD40L concentrations in the serum and the cerebrospinal fluid of patients with tick borne encephalitis and neuroborreliosis Zajkowska JM, etal., Neurol Neurochir Pol. 2006 Jan-Feb;40(1):22-7.
157. [A study of costimulatory molecules in allergic allergic rhinitis patients]. Zhu R, etal., Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008 Sep;22(17):780-2, 784.
158. B cells play a cooperative role via CD40L-CD40 interaction in T cell-mediated experimental autoimmune neuritis in Lewis rats. Zhu W, etal., Neurobiol Dis. 2007 Mar;25(3):642-8. Epub 2006 Dec 22.
Additional References at PubMed
PMID:7529792   PMID:8605945   PMID:8617933   PMID:9468137   PMID:9922218   PMID:12697681   PMID:12885753   PMID:12958312   PMID:14647274   PMID:15067037   PMID:15485634   PMID:15665763  
PMID:17082577   PMID:17976119   PMID:19164932   PMID:21410936   PMID:22017688   PMID:25511433   PMID:25993320   PMID:29155846   PMID:29843579   PMID:31331973  


Genomics

Comparative Map Data
Cd40lg
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.2X135,127,119 - 135,138,302 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 EnsemblX135,126,969 - 135,138,306 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_UtxX137,323,952 - 137,335,135 (+)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.0X140,881,620 - 140,892,805 (+)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.0X138,451,019 - 138,462,204 (+)NCBIRnor_WKY
Rnor_6.0X159,703,703 - 159,714,886 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 EnsemblX159,703,578 - 159,716,562 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0X154,330,893 - 154,341,954 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4X141,925,019 - 141,937,183 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1X141,998,451 - 142,010,616 (+)NCBI
CeleraX143,160,596 - 143,171,765 (+)NCBICelera
Cytogenetic MapXq37NCBI
CD40LG
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh38X136,648,158 - 136,660,390 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 EnsemblX136,648,158 - 136,660,390 (+)EnsemblGRCh38hg38GRCh38
GRCh37X135,730,317 - 135,742,549 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 36X135,558,002 - 135,570,215 (+)NCBINCBI36Build 36hg18NCBI36
Build 34X135,455,855 - 135,468,068NCBI
CeleraX136,094,012 - 136,106,224 (+)NCBICelera
Cytogenetic MapXq26.3NCBI
HuRefX125,001,305 - 125,013,640 (+)NCBIHuRef
CHM1_1X135,641,985 - 135,654,211 (+)NCBICHM1_1
T2T-CHM13v2.0X134,956,900 - 134,969,116 (+)NCBIT2T-CHM13v2.0
Cd40lg
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm39X56,257,503 - 56,269,402 (+)NCBIGRCm39GRCm39mm39
GRCm39 EnsemblX56,257,503 - 56,269,402 (+)EnsemblGRCm39 Ensembl
GRCm38X57,212,143 - 57,224,042 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 EnsemblX57,212,143 - 57,224,042 (+)EnsemblGRCm38mm10GRCm38
MGSCv37X54,465,320 - 54,477,219 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36X53,558,927 - 53,570,826 (+)NCBIMGSCv36mm8
CeleraX43,689,623 - 43,701,548 (+)NCBICelera
Cytogenetic MapXA6NCBI
cM MapX31.21NCBI
Cd40lg
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_0049554898,465,164 - 8,477,746 (-)EnsemblChiLan1.0
ChiLan1.0NW_0049554898,465,571 - 8,477,714 (-)NCBIChiLan1.0ChiLan1.0
CD40LG
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
PanPan1.1X136,042,849 - 136,055,158 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 EnsemblX136,042,849 - 136,058,202 (+)Ensemblpanpan1.1panPan2
Mhudiblu_PPA_v0X125,776,138 - 125,788,820 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
CD40LG
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.1X107,001,421 - 107,023,007 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 EnsemblX107,010,890 - 107,023,006 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_TashaX92,832,126 - 92,844,241 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0X108,980,873 - 109,002,662 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 EnsemblX108,990,551 - 109,002,661 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1X106,131,221 - 106,143,392 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0X108,322,638 - 108,334,748 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0X107,964,432 - 107,976,548 (+)NCBIUU_Cfam_GSD_1.0
Cd40lg
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2X104,994,220 - 105,007,112 (+)NCBIHiC_Itri_2
SpeTri2.0NW_00493651310,607,617 - 10,620,403 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
CD40LG
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 EnsemblX111,778,493 - 111,789,709 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.1X111,778,666 - 111,788,901 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2X127,636,797 - 127,647,035 (+)NCBISscrofa10.2Sscrofa10.2susScr3
CD40LG
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.1X111,655,301 - 111,667,602 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 EnsemblX111,655,397 - 111,666,639 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366606549,341,810 - 49,354,077 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Cd40lg
(Heterocephalus glaber - naked mole-rat)
Naked Mole-rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_00462480810,472,572 - 10,484,338 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_00462480810,472,028 - 10,484,407 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1598837Memor13Memory QTL 133.2exploratory behavior trait (VT:0010471)difference between time of physical contact/close proximity of test subject and social stimulus during sample phase and test phase (CMO:0002678)X41052407146860749Rat
1598872Memor14Memory QTL 144.5exploratory behavior trait (VT:0010471)difference between time of physical contact/close proximity of test subject and social stimulus during sample phase and test phase (CMO:0002678)X93956491138956491Rat
738025Stresp3Stress response QTL 34.610.0066stress-related behavior trait (VT:0010451)defensive burying - approachX100567703150256146Rat
1598809Memor15Memory QTL 154.4exploratory behavior trait (VT:0010471)difference between time of physical contact/close proximity of test subject and social stimulus during sample phase and test phase (CMO:0002678)X103312877148312877Rat
1598856Memor1Memory QTL 11.9exploratory behavior trait (VT:0010471)total horizontal distance resulting from voluntary locomotion in an experimental apparatus (CMO:0001443)X103312877148312877Rat
738029Stresp2Stress response QTL 23.40.0004stress-related behavior trait (VT:0010451)defensive burying - approachX112934952138400867Rat
10059603Bw174Body weight QTL 1743.40.025body mass (VT:0001259)body weight (CMO:0000012)X113937816152453651Rat
634346Insul4Insulin level QTL 40blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)X126975089152453651Rat

miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:100
Count of miRNA genes:83
Interacting mature miRNAs:91
Transcripts:ENSRNOT00000001162
Prediction methods:Microtar, Pita, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium
Low 2 17 1 19 1 1 1 8 9 8 11 1
Below cutoff 1 10 28 28 28 7 9 1 8 6 7

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000001162   ⟹   ENSRNOP00000001162
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 EnsemblX135,126,969 - 135,138,306 (+)Ensembl
Rnor_6.0 EnsemblX159,703,578 - 159,716,562 (+)Ensembl
RefSeq Acc Id: NM_053353   ⟹   NP_445805
RefSeq Status: VALIDATED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2X135,127,119 - 135,138,302 (+)NCBI
Rnor_6.0X159,703,703 - 159,714,886 (+)NCBI
Rnor_5.0X154,330,893 - 154,341,954 (+)NCBI
RGSC_v3.4X141,925,019 - 141,937,183 (+)RGD
CeleraX143,160,596 - 143,171,765 (+)RGD
Sequence:
Protein Sequences
Protein RefSeqs NP_445805 (Get FASTA)   NCBI Sequence Viewer  
GenBank Protein AAD09323 (Get FASTA)   NCBI Sequence Viewer  
  AAD22460 (Get FASTA)   NCBI Sequence Viewer  
  ABK59325 (Get FASTA)   NCBI Sequence Viewer  
  EDL75129 (Get FASTA)   NCBI Sequence Viewer  
  Q9Z2V2 (Get FASTA)   NCBI Sequence Viewer  
Reference Sequences
RefSeq Acc Id: NP_445805   ⟸   NM_053353
- Sequence:
RefSeq Acc Id: ENSRNOP00000001162   ⟸   ENSRNOT00000001162
Protein Domains
TNF_2

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-Q9Z2V2-F1-model_v2 AlphaFold Q9Z2V2 1-260 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13702074
Promoter ID:EPDNEW_R12598
Type:single initiation site
Name:Cd40lg_1
Description:CD40 ligand
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0X159,703,637 - 159,703,697EPDNEW

Strain Variation

Strain Sequence Variants (mRatBN7.2)
ACI/EurMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
ACI/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BN-Lx/CubMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BN/NHsdMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BN/NHsdMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BN/SsN (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BUF/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BXH2/CubMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BXH3/CubMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
DA/OlaHsd (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Envigo
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
F344/DuCrl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
F344/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
F344/NCrl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
F344/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
FHH/EurMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
FXLE16/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
FXLE18/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
GK/FarMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB10/IpcvMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB2/IpcvMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB20/IpcvMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB31/IpcvMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB4/IpcvMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LE/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEW/Crl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF10A/StmMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF11/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF1A/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF1C/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF2B/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF3/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF4/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LH/MavRrrcAek (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Kwitek
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LL/MavRrrcAek (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Kwitek
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LN/MavRrrcAek (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Kwitek
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
M520/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
M520/NRrrcMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
MR/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
MWF/Hsd (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
PVG/Seac (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
SHR/OlalpcvMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
SHRSP/A3NCrl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
SR/JrHsd (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Envigo
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
SS/JrHsdMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
WAG/RijCrl (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
WKY/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
WKY/NCrl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
WN/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:708418 AgrOrtholog
BioCyc Gene G2FUF-907 BioCyc
Ensembl Genes ENSRNOG00000000871 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000001162 ENTREZGENE
  ENSRNOP00000001162.2 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000001162 ENTREZGENE
  ENSRNOT00000001162.5 UniProtKB/TrEMBL
Gene3D-CATH 2.60.120.40 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro CD40L UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TNF_CS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TNF_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tumour_necrosis_fac-like_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:84349 UniProtKB/Swiss-Prot
NCBI Gene 84349 ENTREZGENE
PANTHER PTHR11471:SF5 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam TNF UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Cd40lg PhenoGen
PIRSF TNF_5 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PRINTS CD40LIGAND UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PROSITE TNF_1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TNF_2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
SMART TNF UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP SSF49842 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A0SZW2_RAT UniProtKB/TrEMBL
  CD40L_RAT UniProtKB/Swiss-Prot, ENTREZGENE
UniProt Secondary Q9R254 UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2006-03-30 Cd40lg  CD40 ligand  Tnfsf5  tumor necrosis factor (ligand) superfamily, member 5  Symbol and Name updated 1299863 APPROVED
2004-12-14 Tnfsf5  tumor necrosis factor (ligand) superfamily, member 5  LOC84349  CD40 ligand  Symbol and Name updated 1299863 APPROVED